Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Sequential inhibition of polyamine synthesis

A phase I trial of DFMO (α-difluoromethylornithine) and methyl-GAG [methylglyoxal-bis(guanylhydrazone)]

Summary

Both DFMO and methyl-GAG inhibit sequential enzymatic reactions in the pathway of polyamine biosynthesis. Since polyamines may be important factors in proliferation of cancer cells, we initiated a phase-I study of these agents in patients with advanced cancer. DFMO was given by mouth at a constant daily dose of 4 g/m2 starting on day 1 of the treatment protocol. The dose of methyl-GAG ranged from 200 to 700 mg/m2 administered IV every 2 weeks beginning on day 4. Twenty-two patients were entered into the protocol. Toxic reactions to this therapy were dose-related and included nausea, fatigue, diarrhea, and myelosuppression. One patient with colon cancer experienced a>50% decrease in measurable disease but developed severe myelotoxicity. While DFMO was well tolerated, the combination of drugs appeared to cause substantially more hematologic and gastrointestinal toxicity than encountered during our recent experience with methyl-GAG used alone. We suggest that future studies of this drug combination carefully evaluate levels of polyamines and inhibition of enzymatic activity to minimize toxicity.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Alhonen-Hongisto L, Seppanen P, Janne J (1980) Intracellular putrescine and spermidine deprivation induces increased uptake of the natural polyamines and methylglyoxal bis(guanylhydrazone). Biochem J 192:941

  2. 2.

    Burchenal JH, Warrell R, Hanson K, King C, Smith R (1982) Antitumor effects of inhibitors of the polyamine pathway. Proc 13th Int Cancer Congress, p 103

  3. 3.

    Dave C, Caballes L (1973) Studies on the uptake of methylglyoxal bis(guanylhydrazone) (CH3-G) and spermidine in mouse leukemia sensitive and resistant to CH3-G. Fed Proc 32:736

  4. 4.

    Durie BGM, Salmon SE, Russell DH (1977) Polyamines as markers of response and disease activity in cancer chemotherapy. Cancer Res 37:214

  5. 5.

    Gau TC, Natale RB (1982) In vitro activity of methylglyoxal bis(guanylhydrazone) (MGBG) ± α-DFMO using the human tumor clongenic assay (HTCA). Proc Am Assoc Cancer Res 23:183

  6. 6.

    Heby O, Janne J (1981) Polyamine antimetabolites: biochemistry, specificity, and biological effects of inhibitors of polyamine synthesis. In: Morris DR, Marton LJ (eds) Polyamines in biology and medicine. Marcell Dekker, New York, p 243

  7. 7.

    Horn Y, Beal SL, Walach N, Lubich WP, Spigel L, Marton LJ (1982) Further evidence for the use of polyamines as biochemical markers for malignant tumors. Cancer Res 42:3248

  8. 8.

    Janne J, Alhonen-Hongisto L, Seppanen P, Simes M (1981) Use of polyamine antimetabolites in experimental tumors and in human leukaemia. Med Biol 59:448

  9. 9.

    Kuhn JG, Knight WA, McDaniel TM, Coltman CA, Whitecar JP, Fabian C, Costanzi JJ (1982) Methylglyoxal bis-guanylhydrazone (methyl-GAG) in the management of non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 1:163

  10. 10.

    Luk GD, Goodwin G, Marton LJ, Baylin SB (1981) Polyamines are necessary for the survival of human small-cell lung carcinoma in culture. Proc Nat Acad Sci (USA) 78:2355

  11. 11.

    Mamont PS, Duchesne M-C, Grove J, Bey P (1978) Anti-proliferative properties of DL-alpha-difluoromethylornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Commun 81:58

  12. 12.

    Merrell-Dow Pharmaceuticals Inc. (1981) Investigational drug brochure: alpha-Difluoromethylornithine (DFMO). Merrell-Dow Inc., Cincinatti, OH, USA

  13. 13.

    Warrell RP, Lee BJ, Kempin SJ, Lacher MJ, Straus DJ, Young CW (1981) Effectiveness of methyl-GAG (methylglyoxal bis{guanylhydrazone}) in patients with advanced malignant lymphoma. Blood 57:1011

  14. 14.

    Warrell RP, Burchenal JH (1983) Methylglyoxal bis(guanylhydrazone) (Methyl-GAG): current status and future prospects. J Clin Oncol 1:52

Download references

Author information

Correspondence to Raymond P. Warrell Jr..

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Warrell, R.P., Coonley, C.J. & Burchenal, J.H. Sequential inhibition of polyamine synthesis. Cancer Chemother. Pharmacol. 11, 134–136 (1983). https://doi.org/10.1007/BF00254263

Download citation

Keywords

  • Cancer Cell
  • Colon Cancer
  • Diarrhea
  • Enzymatic Reaction
  • Treatment Protocol